The FDA has granted an advisory committee meeting for BrainStorm Cell Therapeutics’ investigational ALS therapy, NurOwn, the company announced Monday.
BrainStorm Secures FDA Adcomm for ALS Therapy NurOwn Read More »
Una mosca macho se acerca a una flor, se posa encima de lo que cree que es una mosca hembra y se agita. Intenta aparearse, pero no lo consigue. Vuelve a intentarlo. Al final se rinde y se va zumbando, sin éxito. La planta, mientras tanto, ha conseguido lo que quería: polen. La …
La planta que crea moscas falsas capaces de engañar a las verdaderas Read More »
Unos investigadores han descubierto una forma de “traducir” la información cuántica entre distintos tipos de tecnologías cuánticas. Representa una nueva forma de convertir la información cuántica entre el formato utilizado por los ordenadores cu&aa …
En este Short os hablamos del extraño comportamiento de la luz en unas circunstancias muy especiales. …
NRx Pharmaceuticals, Inc., a clinical-stage CNS biopharmaceutical company, reported that the independent Data Safety Monitoring Board reviewed the safety and efficacy findings of the first fifty enrolled participants in the Company’s clinical trial of NRX-101 for the treatment of Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior.
YS Biopharma announced its positive interim Phase II safety and immunogenicity data for its PIKA recombinant COVID-19 Vaccine.
People who dedicate their careers to healthcare often do so because of a deep desire to help others.
IT in healthcare: Enabling a more efficient and satisfied workforce Read More »
Learn how to help address common printing challenges, manage the breadth of printed materials required for internal and external communications and reduce costs.
Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali® plus endocrine therapy in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer at risk of recurrence.
Biophytis SA announced that it has held a presentation on their drug candidate, Sarconeos, as a possibility to cure long COVID after hospitalization, at the 13th annual International Conference on Frailty and Sarcopenia Research.
